Bronchiolitis obliterans following hematopoietic stem cell transplantation: a clinical update.
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and non-malignant conditions. Pulmonary complications, infectious and non-infectious, are a major cause of morbidity and mortality in these patients. The recent advances in prophylaxis and treatment of infectious complications increased the significance of late non-infectious pulmonary conditions. Currently, bronchiolitis obliterans is one of the most challenging pulmonary complications facing clinicians who are taking care of HSCT recipients. This report provides a clinical update of the incidence, risk factors, pathogenesis, clinical characteristics, and management of bronchiolitis obliterans following HSCT.
Pandya
Chirag M
CM
Division of Pulmonary, Critical Care and Sleep Medicine, Karmanos Cancer Center and Wayne State University School of Medicine, Detroit, MI 48201, USA.
Soubani
Ayman O
AO
D001989:Bronchiolitis Obliterans / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D012307:Risk Factors